Multiple sclerosis pharmacogenomics: Maximizing efficacy of therapy

Neurology

Volumn 74, Issue 1 SUPPL., 2010, Pages

  Pappas, Derek J ^a,b   Oksenberg, Jorge R ^a,b  

^a University of California ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; EXTAVIA; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; UNCLASSIFIED DRUG;

ALGORITHM; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; GENETIC POLYMORPHISM; GENOME; HEPATITIS C; HEREDITY; HUMAN; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW;

EID: 74249092274     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181c980fb     Document Type: Article

References (55)

1. McElroy JP, Oksenberg JR. Multiple sclerosis genetics. Curr Top Microbiol Immunol 2008;318:45-72.
2. Kleinschnitz C, Meuth SG, Kieseier BC, Wiendi H. Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006. Endocr Metab Immune Disord Drug Targets 2007;7:35-63.
3. Katz DA, Bhathena A. Overview of pharmacogenetics. Curr Protoc Hum Genet 2009;Chapter 9:Unit 9.19.
4. O'Doherty C, Villoslada P, Vandenbroeck K. Pharmacogenomics of type I interferon therapy: a survey of response-modifying genes. Cytokine Growth Factor Rev 2007; 18: 211-222. (Pubitemid 46900903)
5. Miller A, Avidan N, Tzunz-Henig N, et al. Translation towards personalized medicine in multiple sclerosis. J Neurol Sci 2008;274:68-75.
6. 6. Baranzini SE, Mousavi P, Rio J, et al. Transcription-based prediction of response to IFN β using supervised computational methods. PLoS Biol 2005;3:e2. (Pubitemid 40318117)
7. Giacomini PS, Arnold. DL, Bar-Or A, Antel JP. Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much? Arch Neurol 2009;66:19-20.
8. Rovaris M, Filippi M. Defining the response to multiple sclerosis treatment: the role of conventional magnetic resonance imaging. Neurol Sci 2006;26(suppl 4):S204-S208.
9. Hurwitz BJ. Important sources of variability in clinical studies of neutralizing antibodies against interferon beta. J Neurol Sci 2008;272:8-19.
10. Peterson JW, Trapp BD. Neuropatliobiology of multiple sclerosis. Neurol Clin 2005;23:107-129, vi-vii.
11. Borden EC, Sen GC, Uze G, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007;6:975-990. (Pubitemid 350201788)
12. Neilley LK, Goodin DS, Goodkin DE, Hauser SL. Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology 1996;46:552-554.
13. Brierley MM, Fish EN. Review: IFN-α/β receptor interactions to biologic outcomes: understanding the circuitry. J Interferon Cytokine Res 2002;22:835-845.
14. Matsuyama N, Mishiro S, Sugimoto M, et al. The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol Res 2003;25:221-225. (Pubitemid 36546347)
15. Cunningham S, Graham C, Hutchinson M, et al. Pharmacogenomics of responsiveness to interferon IFN-β treatment in multiple sclerosis: a genetic screen of 1.00 type I interferoninducible genes. Clin Pharmacol Ther 2005;78:635-646. (Pubitemid 41773639)
16. Leyva L, Fernandez O, Fedetz M, et al. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol 2005;163:165-171. (Pubitemid 40692959)
17. Sriram U, Barccllos LF, Villoslada P, et al. Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes Immun 2003;4:147-152. (Pubitemid 38967589)
18. Comabella M, Craig DW, Morcillo-Suárez C, et al. Genomewide scan of 500,000 single-nucleotide polymorphisms among respondcrs and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol 2009;66:972-978.
19. Byun E, Caillier SJ, Montalban X, et al. Genome-wide pharmacogcnomic analysis of the response to interferon β therapy in multiple sclerosis. Arch Neurol 2008;65:337-344.
20. Beck H, Schwarz G, Schroter CJ, et al. Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro. Eur J Immunol 2001;31:3726-3736. (Pubitemid 34030986)
21. Sugimoto Y, Kuzushita N, Takehara T, et al. A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C. J Viral Hepat 2002;9: 377-384. (Pubitemid 35056590)
22. Knapp S, Yee LJ, Frodsham AJ, et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun 2003;4:411-419. (Pubitemid 38967606)
23. Billiau A. Anti-inflammatory properties of type I interferons. Antiviral Res 2006;71:108-116.
24. King JK, Yeh SH, Lin MW, et al. Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: a pilot study. Hepatology 2002;36: 1416-1424. (Pubitemid 35403532)
25. Weinstock-Guttman B, Tamaño-Blanco M, Bhasi K, Zivadinov R, Ramanathan M. Pharmacogenetics of MXA SNPs in interferon-β treated multiple sclerosis patients. J Neuroimmunol 2007;182:236-239. (Pubitemid 46026717)
26. Chen J, Liu X. The role of interferon b in regulation of CD4+ T-cells and its clinical implications. Cell Immunol 2009;254:85-90.
27. Martínez A, de las Heras V, Mas Fontao A, et al. An IFNG polymorphism is associated with interferon-beta response in Spanish MS patients. J Neuroimmunol 2006;173:196-199.
28. Pravica V, Asderakis A, Perrey C, Hajeer A, Sinnott PJ, Hutchinson IV. In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene. Eur J Immunogenet 1999;26:1-3.
29. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999;30:526-530. (Pubitemid 29357520)
30. Yee LJ, Tang J, Gibson AW, Kimberly R, Van Leeuwen DJ, Kaslow RA. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001;33:708-712. (Pubitemid 32185234)
31. Abbas Z, Moatter T, Hussainy A, Jafri W. Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3. World J Gastroenterol 2005;11: 6656-6661. (Pubitemid 43072706)
32. Wergeland S, Beiske A, Nyland H, et al. IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. Eur J Neurol 12:171-175, 2005. (Pubitemid 40278522)
33. Wiesemann E, Deb M, Hemmer B, Radeke HH, Windhagen A. Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis. Clin Immunol 2008;128:306-313.
34. Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009;8:280-291.
35. Kieseier BC, Hartung HP. Interferon-beta and neuroprotection in multiple sclerosis - facts, hopes and phantasies. Exp Neurol 2007;203:1-4.
36. Cénit MD, Bianco-Kelly F, de las Heras V, et al. Glypican 5 is an interferon-beta response gene: a replication study. Mult Scler 2009;15:913-917.
37. Stürzebecher S, Wandinger KP, Rosenwald A, et al. Expression profiling identifies responder and non-responder phenotypes to interferon-β; in multiple sclerosis. Brain 2003;126:1419-1429. (Pubitemid 36644386)
38. Weinstock-Guttman B, Bhasi K, Badgett D, et al. Genomic effects of once-weekly, intramuscular interferon-β1a treatment after the first dose and on chronic dosing: relationships to 5-year clinical outcomes in multiple sclerosis patients. J Neuroimmunol 2008;205:113-125.
39. Lindberg RL, Achtnichts L, Hoffmann F, Kuhle J, Kappos L. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 2008;194:153-164.
40. Comabella M, Lünemann JD, Río J, et al. A type I interferon signature in monocytes is associated with poor response to interferon-{beta} in multiple sclerosis. Brain Epub 2009 Sep 9.
41. Prinz M, Schmidt H, Mildner A, et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008;28:675-686.
42. Blanchette F, Neuhaus O. Glatiramer acetate: evidence for a dual mechanism of action. J Neurol 2008; 255(suppl 1):26-36. (Pubitemid 351341870)
43. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971;1:242-248.
44. Fusco C, Andreone V, Coppola G, et al. HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis. Neurology 2001;57:1976-1979. (Pubitemid 33126861)
45. Grossman I, Avidan N, Singer C, et al. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenet Genomics 2007; 17:657-666. (Pubitemid 47057715)
46. Villoslada P, Barcellos LF, Río J, et al. The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-β. J Neuroimmunol 2002;130:194-201. (Pubitemid 35240007)
47. Comabella M, Fernández-Arquero M, Río J, et al. HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis. J Neuroimmunol 2009;210:116-119.
48. Valenzuela RM, Costello K, Chen M, Said A, Johnson KP, Dhib-Jalbut S. Clinical response to glatiramer acetate correlates with modulation of IFN-γ and IL-4 expression in multiple sclerosis. Mult Scler 2007;13:754-762. (Pubitemid 47074099)
49. Neuhaus O, Kieseier C, Hartung HP. Immunosuppressive agents in multiple sclerosis. Neurotherapeutics 2007;4: 654-660.
50. Tamura A, Wakabayashi K, Onishi Y, et al. Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci 2007;98:231-239. (Pubitemid 44941876)
51. Nayak MS, Yang JM, Hait WN. Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. Cancer Res 2007;67:5831-5839.
52. Elliott JI, Raguz S, Higgins CF. Multidrug transporter activity in lymphocytes. Br J Pharmacol 2004;143:899-907.
53. Moller MB. Molecular control of the cell cycle in cancer: biological and clinical aspects. Dan Med Bull 2003;50: 118-138.
54. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 1992;356:63-66.
55. Lutterotti A, Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol 2008;7:538-547. (Pubitemid 351657494)